Physician profile
Tom Byrd
NPI 1164458980
$1,603.23
in general payments reported to CMS, 2019-2025
27 companies · $73.22 in 2025
The $73.22 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $186 · 2021: $331 · 2022: $266 · 2023: $265 · 2024: $372 · 2025: $73.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.82 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.82 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $225.85 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Stryker Corporation | $217.19 | 2019-2024 | Inspace |
| Lilly USA, LLC | $161.65 | 2020-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $119.97 | 2020-2024 | Xarelto |
| Pfizer INC. | $101.86 | 2023-2025 | |
| Collaborative Care Diagnostics, LLC | $64.67 | 2019 | |
| Novo Nordisk INC | $49.43 | 2020-2023 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $38.18 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.37 | 2022 | |
| Glaxosmithkline, LLC. | $25.09 | 2021-2022 | |
| Abbott Laboratories | $24.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.56 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.75 | 2023 | Givlaari |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.07 | 2020 | |
| Medtronic, INC. | $17.48 | 2021 | |
| Allergan, INC. | $16.88 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.70 | 2024 | |
| Recordati_rare_diseases_inc. | $14.04 | 2023 | Panhematin |
| Organon LLC | $13.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.48 | 2023 | Austedo Xr |
| Astellas Pharma US INC | $13.40 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $12.70 | 2021 | |
| Redhill Biopharma INC. | $12.31 | 2020 | |
| Dexcom, INC. | $11.30 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.